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chemoradiotherapy, while 32% had primary surgery. 30% were current
tobacco users and 70% had ever used tobacco (mean = 43.33 PY). 15%
of patients reported marijuana use at time of initial diagnosis and 34%
reported a history of marijuana use. Older patients and males were
more likely to be currently using marijuana (p=.005 & p=.04, respectively). Current marijuana users were more likely to require narcotic
pain medications and require a greater number of types of pain medications during treatment (p=0.002 and p=0.007, respectively). There
were no differences between current and historical/never users on selfreported worst pain, weight loss or enteral feeding tube use during
treatment, or objective measures of treatment toxicity. Additionally,
there were no other signiﬁcant differences between current or historical/never users were found on cancer variables or primary treatment
type.
Conclusion: Marijuana use in patients with HNSCCa is common and
little is known about patient and oncological outcomes. There were no
signiﬁcant differences between current and past marijuana users and
non-users on clinicopathological variables, adherence, or oncologic
outcomes. Marijuana use in HNC may result in more difﬁculty managing pain during treatment. Further research is needed to better understand marijuana use during cancer treatment, particularly frequency
and method of use (i.e., smoking vs. edibles/oils), outcomes, and quality of life.
Author Disclosure: A.M. Williams: None. M. Gilbert: None. F. Siddiqui:
Employee; Children's Hospital of Michigan. Research Grant; Varian Medical Systems, Inc. Honoraria; Varian Medial Systems Inc, Varian Medical
Systems, Inc., American College of Radiology. Speaker's Bureau; Varian
Medial Systems Inc. Advisory Board; Varian Noona. Travel Expenses; Varian Medial Systems Inc, Varian Medical Systems, Inc. HF.
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Health Insurance Literacy in Head and Neck Cancer Patients
K. Patel,1 R. McCormick,1 L. Kim,2 A. Otto,3 A. Alishahi Tabriz,1
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K. Turner1; 1Mofﬁtt Cancer Center, Tampa, FL, 2University of South Florida, Tampa, FL, 3University of Miami, Miami, FL, 4University of Florida,
Gainseville, FL, 5The James Cancer Hospital and Solove Research Institute,
Wexner Medical Center at The Ohio State University, Department of Otolaryngology-Head and Neck Surgery, Columbus, OH, 6Department of Otolaryngology−Head and Neck Surgery, University of Western Ontario, London,
ON, Canada, 7University of Vermont, Burlington, VT
Purpose/Objective(s): Cancer is the second most costly medical condition
in the U.S., putting many patients at risk for ﬁnancial hardship. Cancer
patients spend more on healthcare, have greater productivity losses, and
are more likely to declare bankruptcy than people without cancer. Financial
hardship has devastating consequences for cancer patients including lower
quality of life, treatment delay or discontinuation, and increased mortality.
Understanding what types of services are covered and how to select an
insurance plan may be beneﬁcial for cancer patients and help reduce ﬁnancial hardship. The purpose of this study was to assess health insurance literacy in patients with head and neck cancer.
Materials/Methods: Newly diagnosed Head and Neck Cancer Patients
were prospectively recruited prior to starting their treatment. Health Insurance Literacy Measure (HILM) scale was administered to patients at the
time of enrollment. HIL comprises of 4 different sections − choosing insurance plan, comparing insurance plan, understanding insurance plan, and
using insurance plan. The scale is rated from 1 (not at all conﬁdent) to 4
(very conﬁdent).
Results: A total of 42 patients completed HILM questionnaire. When
patients were asked about their ability to: choose an insurance plan −
40.08% (26.19% − 66.67%) responded as not conﬁdent or slightly conﬁdent; compare insurance plans − 31.75% (26.19% - 38.10%) responded as
not conﬁdent or slightly conﬁdent; understand insurance plans − 47.14%
(40.48% - 50.0%) responded as not conﬁdent or slightly conﬁdent; and use
their insurance plan − 40.47% (33.33% - 57.14%) responded as not
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conﬁdent or slightly conﬁdent. From each category, top question which
patients did not feel conﬁdent or slightly conﬁdent included: “You know
where to go for help if you were having trouble affording health insurance
outside of an employer?” (choosing insurance plan); “Understand what you
would have to pay for specialist visits?” (comparing insurance plans); You
know how to ﬁnd out what is and is not covered before you receive a health
care service? (understanding insurance plans); and “Look into what your
health plan will and will not cover before you get health care services?”
(using insurance plans).
Conclusion: A signiﬁcant portion of patients demonstrate limited understanding in their ability in choosing, comparing, understanding, and using
their insurance plans. Educating patients and their caregivers to improve
their health insurance literacy may help patients with their ﬁnancial toxicity
and alleviate anxiety associated with ﬁnancial distress.
Author Disclosure: K. Patel: None. R. McCormick: None. L. Kim: None.
A. Otto: None. A. Alishahi Tabriz: None. Y. Hong: None. J.W. Rocco:
None. A. Nichols: None. X. Wang: None. H. Jim: Research Grant; Kite
Pharma. M. Reblin: None. K. Turner: None.
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Does Cetuximab Reduce the Risk of Anemia in Patients
Undergoing Radiation Therapy for Head and Neck Cancers?
A.I. Ghanem,1,2 L. Maahs,3 R. Gutta,3 A. Tang,4 M. Gilbert,1 S. Arya,3
Z.A. Saheli,3 S. Tam,5 J. Sheqwara,6 and F. Siddiqui1; 1Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI, 2Alexandria Clinical Oncology Department, Alexandria University, Alexandria, Egypt,
3
Department of Internal Medicine, Henry Ford Hospital, Detroit, MI,
4
Department of Public Health Sciences, Henry Ford Health System, Detroit,
MI, 5Department of Otolaryngology, Henry Ford Cancer Institute, Detroit,
MI, 6Department of Hematology/Oncology, Henry Ford Cancer Institute,
Detroit, MI
Purpose/Objective(s): Epidermal growth factor receptor (EGFR) activation is associated with increased production of interleukin 6 (IL6), which is
intensiﬁed by radiotherapy (RT) induced inﬂammatory response. Elevated
IL6 levels promote RT-induced anemia by upregulating hepcidin causing
functional iron deﬁciency. Cetuximab, an EGFR inhibitor, resulted in signiﬁcantly lower rates of RT induced anemia for locally advanced head and
neck squamous cell carcinoma (HNSCC) patients receiving deﬁnitive RT
vs RT-alone according to Bonner et al; and other studies compared to concomitant chemotherapy. However, little is known for cases receiving cetuximab with RT in the adjuvant setting.
Materials/Methods: We queried our institutional HNSCC database for
surgically staged non-metastatic cases that received adjuvant RT with or
without concomitant cetuximab between 2006-2018. Cetuximab was
administered for some high-risk cases medically unﬁt for platinum agents
per multidisciplinary team evaluation. All included patients need to have at
least one complete blood count pre- and post-RT end. We compared RTcetuximab vs RT-alone for prevalence of baseline and post-RT anemia,
deﬁned as Hb below 12g/dL in females and 13g/dL in males, and mean
hemoglobin (Hb) levels. We also assessed the improvement in Hb level
post-RT (resolution of baseline anemia or Hb increase of at least 1g/dL
above baseline), in addition to overall survival (OS) in relation to anemia/
Hb dynamics.
Results: We were able to identify 66 patients who ﬁt our inclusion criteria,
of which 27 (41%) received RT-cetuximab, with the remaining receiving
RT-alone (n=39, 59%). Median age was 62.5 years (range, 34-88 years),
males 80%, black 29%, and 85% had a smoking history. The majority of
cases (73%) were locally advanced. Oral cavity and oropharynx were the
most common subsites (37.5% each), with HPV+ve cases representing 52%
of the later. The study groups were well-balanced, except for higher rates of
positive ﬁnal surgical margins, and extracapsular space invasion and
median RT dose (p<0.05). Baseline anemia was diagnosed in 70.4% in RTcetuximab vs 76.9% in the RT-alone, p=0.76; with similar mean Hb level
(11.7g/dL in both). Meanwhile, baseline iron, vitamin-B12 and folate deﬁciencies, and chronic kidney disease were non-different. After completion
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of RT, mean Hb was signiﬁcantly higher in the RT-alone (12.9§1.4 g/dL)
compared to RT-Cetuximab (11.9§2.1 g/dL), p=0.02. Nevertheless, higher
anemia levels (70% vs 51%) and lower improvement of Hb post-RT (81.5%
vs 92.3%) were both non-signiﬁcant for RT-cetuximab vs RT-alone respectively, p>0.05 for both. On multivariate analysis, baseline anemia was associated with worse OS (p=0.0052), unlike improvement of Hb post-RT
(p=0.14) with a corresponding better improvement of Hb (56.4% vs. 25.9%,
p=0.014), albeit lower anemia levels (70% vs. 51%), was non signiﬁcant
(p=0.195). On multivariate analysis, lack of baseline anemia was associated
with better OS (p=0.0052), whereas improvement of Hb post-RT was only
marginal (p=0.068).
Conclusion: In a homogenous cohort of HNSCC patients treated postoperatively, concomitant cetuximab was not associated with lower RTinduced anemia, in contrast to previous studies.
Author Disclosure: A.I. Ghanem: None. L. Maahs: None. R. Gutta: None.
A. Tang: None. M. Gilbert: None. S. Arya: None. Z.A. Saheli: None. S. Tam:
None. J. Sheqwara: None. F. Siddiqui: Employee; Children's Hospital of
Michigan. Research Grant; Varian Medical Systems, Inc. Honoraria; Varian
Medial Systems Inc, Varian Medical Systems, Inc., American College of
Radiology. Speaker's Bureau; Varian Medial Systems Inc. Advisory Board;
Varian Noona. Travel Expenses; Varian Medial Systems Inc, Varian Medical Systems, Inc. HF.
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(range 1.91 to 28.5 months). During follow up, 41 patients (20.5%) developed at least one major toxicity. In multivariable analyses, for each signiﬁcant HRQoL scales adjusted on model based on clinical and
sociodemographic data (age, Center with at least 30 patients included, cancer site, cancer stage, chemotherapy and surgery), a 10-point increase score
in the FP (HR: 0.76, 95% CI [0.62 to 0.94], p=0.009), role functioning (HR:
0.87, 95% CI [0.77 to 0.98], p=0.032) and social functioning (HR: 0.88, 95%
CI [0.77 to 0.99], p=0.047) were associated with a lower risk of occurrence
of major toxicities, while a 10-point increase score in dyspnea (HR: 1.15,
95% CI [1.03 to 1.30], p=0.014), and loss of appetite (HR: 1.16, 95% CI
[1.03 to 1.32], p=0.013) were associated with an increased risk of occurrence of major toxicities
Conclusion: Some baseline HRQoL scores were predictive factors of major
toxicities and HRQOL should be assessed before treatment to identify
patients at risk to develop radiotherapy related toxicities in patients with
HNC.
Author Disclosure: O. Billa: None. F. Bonnetain: None. J. Chamois:
None. A. Ligey: None. V. Ganansia: None. S. Renard: None. M. Quivrin:
None. P. Truntzer: None. N. Vulquin: None. G. Noel: None. P. Maingon:
None. S.T. Dabakuyo-Yonli: None.
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Predictive Value of Health-Related Quality of Life on
Radiotherapy Related Toxicities in Patients with Head and
Neck Cancer
O. Billa,1 F. Bonnetain,2 J. Chamois,3 A. Ligey,4 V. Ganansia,5 S. Renard,6
M. Quivrin,7 P. Truntzer,5 N. Vulquin,7 G. Noel,5 P. Maingon,8 and
S.T. Dabakuyo-Yonli1; 1Epidemiology and Quality of Life Unit, GeorgesFrançois Leclerc Cancer Centre, Dijon, France, 2Methodological and Quality
of Life in Oncology Unit, INSERM UMR 1098, University Hospital of Besancon, France, Besancon, France, 3Centre Hospitalier Saint Gregoire, Saint
Gregoire, France, 4Hopital bourg en bresse, Saint Denis les Bourg, RhoneAlpe, France, 5Paul Strauss Cancer Centre-Unicancer, Strasbourg, France,
6
Institut de Cancerologie de Lorraine, Nancy, France, 7Radiotherapy department. Georges-François Leclerc Cancer Centre, Dijon, France, 8Department
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Purpose/Objective(s): aims to assess the association between baseline
HRQOL and occurrence of major toxicities in patients with head and neck
cancer (HNC).
Materials/Methods: The present study analyzed data from randomized
study investigating the utility of HRQoL assessment. Patients with HNC
treated by radiotherapy were included from May 2009 to September 2014
in 4 centers in France. At baseline and during follow-up patients were completed QLQ-C30 questionnaire. According to NCI-CTCAE classiﬁcation,
we deﬁned major toxicities as adverse events of grade ≥3 including skin,
digestive, general, hematological head/neck toxicities and death related to
an adverse event. Cox proportional-hazards regression analyses were performed in two step to assess association between baseline HRQoL score
and major toxicities. Firstly Manual backward selection was performed to
determine clinical and sociodemographic factors associated with major toxicities with a p-value <0.05 by multivariable analysis. Secondly each baseline HRQOL dimension selected in univariable have been adjusted on
variables included in multivariable model based on clinical and sociodemographic data to determine predictive value of HRQOL on major toxicities
and value of p <0.05 was considered as statistically signiﬁcant. The HRQOL
scores were included as continuous variables and hazard ratios were calculated for each increase of 10 points in HRQOL.
Results: Out of 200 patients included, the median age was 59.6 years,
79.5% had comorbidities, 55.6% received adjuvant chemotherapy and
90.4% underwent surgery. At baseline, global health status mean score was
67.03 (SD=19.28), the best functioning score was physical functioning (FP)
with means of 87.92 (24.35) and the worst symptom score was insomnia
with mean score of 31.67 (32.06). The median follow-up was 24 months
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London, ON, Canada
Purpose/Objective(s): In addition to chemotherapy toxicities, most HNC
patients receiving CRT experience moderate to severe radiation-induced
pharyngitis. Management includes escalating analgesics, dietary modiﬁcation, supplemental hydration, and feeding tubes for nutritional support as
needed. Uncontrolled symptoms can interrupt or truncate curative intent
treatment, impacting both quality of life and cancer outcomes. In 2014, a
fulltime NP role dedicated to symptom management during and immediately post-CRT was initiated at our center. We assessed the impact on
patient Emergency Department (ER) visits, hospitalizations and deaths.
Materials/Methods: Patients receiving deﬁnitive primary CRT with curative intent were identiﬁed during 12 month periods prior to (April 2012March 2013) and three years after (April 2017-March 2018) initiation of
the NP from records of H&N MDT case conferences. We hypothesized
that ER visits and hospitalizations would be reduced with NP care. Effects
on treatment delivery were secondary outcomes. Patient demographic,
tumor, treatment, ER visit, hospital admission, and mortality data were
extracted retrospectively from the electronic medical record. Unadjusted
comparisons were done using the chi-square test for categorical variables
and t-test for continuous variables with p<0.05 considered of signiﬁcance.
This project was approved by the institutional REB.
Results: 105 and 120 patients were identiﬁed in the pre-NP and post-NP
cohorts, respectively. Post-NP patients were younger (mean age 63.2 vs
67.3 years), more often had oropharyngeal cancer (81.5% vs 56.2%), did
not receive weekly carboplatin (0.0% vs 8.6%), and received cisplatin scheduled q3weekly less often (45.0% vs 71.4%) and weekly more often (48.3% vs
16.2%). Patients received a mean of 3.6 visits and 4.3 phone calls with the
NP. There was no difference in ER visits within 42 days of treatment
between cohorts (55.2% vs 55.8%). However, hospital admissions were
reduced (60.0% vs 45.8%, p=0.034). Length of stay was similar, and there
was no difference in 90-day mortality (2.9% vs 2.5%).
Conclusion: This before-and-after study showed a 23.7% reduction in hospitalizations after introduction of the NP role, consistent with the ﬁndings
of others (Terzo 2017). Over 50% of patients visited the ER at least once
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